Skip to content

Glin3: Assessment of the Glycemic Responses to Nutritional Products

Determination of the Postprandial Glycemic Response and Glycemic Index of Nutritional Products: A Randomized Controlled Clinical Trial in Healthy Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06215534
Acronym
GLIN#3
Enrollment
12
Registered
2024-01-22
Start date
2024-02-07
Completion date
2024-06-12
Last updated
2024-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glycemic Response

Keywords

Glycemic response, Glycemic Index, Nutritional products, Healthy individuals

Brief summary

This study assesses the glycemic responses to nutritional products. During a study visit fasted subjects will consume one serving of the reference product or the test product. Capillary blood samples will be taken at baseline and at several time-points over a 2-hr period. Several nutritional products will be tested over time.

Interventions

DIETARY_SUPPLEMENTfirst reference product series 1

dextrose (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENTsecond reference product seies 1

dextrose (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENTthird reference product series 1

dextrose (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENTfirst concept product series 1

Standard tube feed (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENTsecond concept product series 1

Tube feed with added fibers (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENTthird concept product series 1

Tube feed with extra energy (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT4th concept product seris 1

Tube feed with extra energy and added fibers (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT5th concept product series 1

Plant based oral nutritional supplement for disease related malnutrition (containing 25 grams of carbohydrates

DIETARY_SUPPLEMENT6th concept product series 1

Oral nutritional supplement for disease related malnutrition in patients with malabsorption and/or maldigestion (containing 25 grams of carbohydrates

DIETARY_SUPPLEMENT1st reference product series 2

dextrose (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT2nd reference product series 2

dextrose (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT3rd reference product series 2

dextrose (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT1st concept product series 2

High energy plant based tube feed (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT2nd concept product series 2

High energy plant based tube feed with added fibers (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT3rd concept product series 2

High protein tube feed (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT4th concept product series 2

High protein, high energy tube feed based on peptides (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT5th concept product series 2

Oral nutritional supplement for disease related malnutrition in patients with muscle loss (containing 25 grams of carbohydrates)

DIETARY_SUPPLEMENT6th concept product series 2

Oral nutritional supplement for disease related malnutrition (containing 25 grams of carbohydrates)

Sponsors

Nutricia Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Intervention model description

12 products will be tested (2 x 6 products + each 3 contls) that means 18 ärmsin total

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Age ≥ 18 and ≤ 65 years * Body mass index (BMI) between 18.5 and 27 kg/m²

Exclusion criteria

* Baseline fasting Glucose ≥6.1 at screening visit * Known history of gastrointestinal disease, bariatric surgery, AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), or any condition which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results. * Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or any medication which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results. * Major trauma or surgical event within 3 months of screening. * Known intolerance, sensitivity or allergy to test products. * Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.). * History of cancer in the prior two years, except for non-melanoma skin cancer.

Design outcomes

Primary

MeasureTime frame
The glycemic index of nutritional products6 months

Secondary

MeasureTime frame
1. The postprandial glucose levels at each time point after each test product compared with the mean of the 3 references6 months
2. The postprandial incremental area under the curve (iAUC) after each test product compared with the mean of the 3 references6 months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026